Vimarsana
Biggest News Aggregation in the World

Paula Pohlmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Paula Pohlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Paula Pohlmann Today - Breaking & Trending Today

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) | Region - Vimarsana News

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) | Region

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention

Jaguar Health, Inc.: Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea - Vimarsana News

Jaguar Health, Inc.: Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea

Jaguar Health subsidiary Napo Pharmaceuticals' OnTarget trial adding international sites, targeting completion of enrollment in Q2 2023SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2022 / Jaguar Health

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer - Vimarsana News

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

/PRNewswire/ -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer - Vimarsana News

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 /PRNewswire/ -- ALX Oncology Holdings Inc., ('ALX Oncology') (Nasdaq: ALXO) a clinical-stage immuno-onc...

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer - Vimarsana News

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 -- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap... | August 15, 2022